{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "23564573",
  "DateCompleted": {
    "Year": "2013",
    "Month": "09",
    "Day": "25"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2013",
        "Month": "04",
        "Day": "20"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "2185-2243",
      "JournalIssue": {
        "Volume": "38",
        "Issue": "1",
        "PubDate": {
          "Year": "2013",
          "Month": "Apr",
          "Day": "20"
        }
      },
      "Title": "The Tokai journal of experimental and clinical medicine",
      "ISOAbbreviation": "Tokai J Exp Clin Med"
    },
    "ArticleTitle": "Long-term glycemic control in Japanese type 2 diabetes patients after switching treatment from twice-daily premixed insulin to once daily insulin glargine.",
    "Pagination": {
      "StartPage": "28",
      "EndPage": "32",
      "MedlinePgn": "28-32"
    },
    "Abstract": {
      "AbstractText": [
        "To examine the clinical utility of once-daily insulin glargine, we studied the clinical course of patients who were switched to from twice-daily premixed insulin to once daily insulin glargine.",
        "The study was conducted at Tokai University hospital in 20 patients with type 2 diabetes, whose treatment regimens were switched from twice-a-day premixed insulin formulation to once-a-day insulin glargine. Changes in various clinical indexes were studied during a 3-year period after the switch. We also compared the well-controlled group (hemoglobin A1c, HbA1c, levels maintained at less than 6.9%) and poorly-controlled group (HbA1c levels at 7.4% or higher).",
        "During the 3-year period, all patients showed significant decrease in HbA1c levels and tendency for reduced daily dose of insulin. Although both BMI and insulin dose tended to decrease in the well-controlled group, they increased in the poorly controlled group.",
        "The findings suggest that in type 2 diabetes, once-a-day insulin glargine could be more useful than twice-a-day premixed insulin formulation. Poor adherence was observed in the poorly-controlled group, namely lack of thoroughness in self-monitoring of blood glucose and adherence to diet and exercise therapy, thus emphasizing the importance of diabetes education."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. umechan@is.icc.u-tokai.ac.jp"
          }
        ],
        "LastName": "Umezono",
        "ForeName": "Tomoya",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Suzuki",
        "ForeName": "Daisuke",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kuriyama",
        "ForeName": "Yusuke",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Miyauchi",
        "ForeName": "Masaaki",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kimura",
        "ForeName": "Moritsugu",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Tanaka",
        "ForeName": "Eitaro",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sato",
        "ForeName": "Hiroki",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Miyatake",
        "ForeName": "Han",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kondo",
        "ForeName": "Masumi",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Toyoda",
        "ForeName": "Masao",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Fukagawa",
        "ForeName": "Masafumi",
        "Initials": "M"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Japan",
    "MedlineTA": "Tokai J Exp Clin Med",
    "NlmUniqueID": "7704186",
    "ISSNLinking": "0385-0005"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Blood Glucose"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Hypoglycemic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Insulin"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Insulin, Long-Acting"
    },
    {
      "RegistryNumber": "2ZM8CX04RZ",
      "NameOfSubstance": "Insulin Glargine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged, 80 and over"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Asian People"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Blood Glucose"
    },
    {
      "QualifierName": [
        "blood",
        "drug therapy"
      ],
      "DescriptorName": "Diabetes Mellitus, Type 2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Substitution"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Hypoglycemic Agents"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Insulin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Insulin Glargine"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Insulin, Long-Acting"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Retrospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}